December 5, 2025 

Dear Director Vought and Administrator Cole,

We write to express our deep concern about the impending lapse of the Drug Enforcement Administration (DEA) telemedicine flexibility that has allowed patients to safely access needed medications. We appreciate that a fourth temporary extension is pending and currently under OMB review. We strongly urge you to immediately act to prevent avoidable lapses in treatment and protect continuity of care for millions who rely on these services.

Since expanded by the Trump Administration, telemedicine has proven to be a lifeline by allowing providers to reach patients where they are, reducing delays in treatment, and improving outcomes. We have seen firsthand how technology-enabled care strengthens the provider-patient relationship, increases adherence to treatment plans, and helps patients lead healthier lives. This progress must not be undone.

View the full letter